Andrea E Wahner Hendrickson, MD

Assistant Professor

  • 777 Citations
  • 14 h-Index
19982019
If you made any changes in Pure, your changes will be visible here soon.

Fingerprint Fingerprint is based on mining the text of the experts' scientific documents to create an index of weighted terms, which defines the key subjects of each individual researcher.

  • 7 Similar Profiles
Neoplasms Medicine & Life Sciences
Ovarian Neoplasms Medicine & Life Sciences
tanespimycin Medicine & Life Sciences
gemcitabine Medicine & Life Sciences
Somatomedin Receptors Medicine & Life Sciences
Emergencies Medicine & Life Sciences
letrozole Medicine & Life Sciences
Insulin Receptor Medicine & Life Sciences

Network Recent external collaboration on country level. Dive into details by clicking on the dots.

Research Output 1998 2019

  • 777 Citations
  • 14 h-Index
  • 27 Article
  • 1 Review article

53BP1 as a potential predictor of response in PARP inhibitor-treated homologous recombination-deficient ovarian cancer

Hurley, R. M., Wahner Hendrickson, A. E., Visscher, D. W., Ansell, P., Harrell, M. I., Wagner, J. M., Negron, V., Goergen, K. M., Maurer, M. J., Oberg, A. L., Meng, X. W., Flatten, K. S., De Jonge, M. J. A., Van Herpen, C. D., Gietema, J. A., Koornstra, R. H. T., Jager, A., den Hollander, M. W., Dudley, M., Shepherd, S. P. & 2 othersSwisher, E. M. & Kaufmann, S. H., Jan 1 2019, (Accepted/In press) In : Gynecologic Oncology.

Research output: Contribution to journalArticle

Homologous Recombination
Ovarian Neoplasms
DNA End-Joining Repair
Neoplasms
Gene Deletion

Can Poly (ADP-Ribose) Polymerase Inhibitors Palliate Paclitaxel-Induced Peripheral Neuropathy in Patients With Cancer?

Balko, R. A., Wahner Hendrickson, A. E., Grudem, M. E., Klampe, C. M. & Jatoi, A., Jan 1 2019, In : American Journal of Hospice and Palliative Medicine. 36, 1, p. 72-75 4 p.

Research output: Contribution to journalArticle

Peripheral Nervous System Diseases
Paclitaxel
Pain
Neoplasms
Hypesthesia
4 Citations (Scopus)

A phase i clinical trial of the Poly(ADP-ribose) polymerase inhibitor veliparib and weekly topotecan in patients with solid tumors

Wahner Hendrickson, A. E., Menefee, M. E., Hartmann, L. C., Long, H. J., Northfelt, D. W., Reid, J. M., Boakye-Agyeman, F., Kayode, O., Flatten, K. S., Harrell, M. I., Swisher, E. M., Poirer, G. G., Satele, D., Allred, J., Lensing, J. L., Chen, A., Ji, J., Zang, Y., Erlichman, C., Haluska, P. & 1 othersKaufmann, S. H., Feb 15 2018, In : Clinical Cancer Research. 24, 4, p. 744-752 9 p.

Research output: Contribution to journalArticle

Topotecan
Clinical Trials
Neoplasms
Maximum Tolerated Dose
Mutation
1 Citations (Scopus)

Cardiovascular Concerns in BRCA1 and BRCA2 Mutation Carriers

Gast, K. C., Viscuse, P. V., Nowsheen, S., Haddad, T. C., Mutter, R., Wahner Hendrickson, A. E., Couch, F. J. & Ruddy, K. J., Feb 1 2018, In : Current Treatment Options in Cardiovascular Medicine. 20, 2, 18.

Research output: Contribution to journalReview article

Mutation
Radiotherapy
Thorax
Guidelines
Drug Therapy
Weight Loss
Weight Gain
Neoplasms
Weights and Measures
Tomography